Axsome Therapeutics Inc
AXSMHealthcare|Biotechnology|USA
$233.80
-15.15 (-6.09%)
Tangible Book
$0.07
Clinical Trials (38)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06223880 A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Major Depressive Disorder | P4 | Recruiting | 350 | RCT, Double-blind | AXS-05, Bupropion |
| NCT07398417 Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | Fibromyalgia | P3 | Recruiting | 620 | RCT, Double-blind | AXS-14 (Esreboxetine), Placebo |
| NCT07484217 Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | P3 | Recruiting | 508 | RCT, Double-blind | Solriamfetol 150 MG, Placebo |
| NCT06413433 Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | Binge-Eating Disorder | P3 | Recruiting | 450 | RCT, Double-blind | Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo |
| NCT06568367 Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | Excessive Sleepiness, Shift-work Disorder | P3 | Recruiting | 520 | RCT, Double-blind | Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo |
| NCT07523048 Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder | Major Depressive Disorder (MDD) | P2 | Recruiting | 30 | Open-label | Dextromethorphan-Bupropion |
| NCT06170970 Solriamfetol for the Treatment of Multiple Sclerosis Fatigue | Multiple Sclerosis, Multiple Sclerosis Fatigue | P2 | Recruiting | 46 | RCT, Double-blind | Solriamfetol, Placebo |
| NCT06413420 SUNOSI® (Solriamfetol) Pregnancy Registry | Narcolepsy, Obstructive Sleep Apnea | Recruiting | 1,731 | — | Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants | |
| NCT05838430 Solriamfetol and CBT-I in Patients With Insomnia Disorder | Insomnia | P4 | Completed | 115 | RCT, Double-blind | Solriamfetol 75 MG |
| NCT04788953 Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder | Excessive Sleepiness, Shift-work Disorder | P4 | Terminated | 84 | RCT, Double-blind | Solriamfetol Oral Tablet, Placebo |
| NCT04789174 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study | Excessive Daytime Sleepiness, Obstructive Sleep Apnea | P4 | Completed | 59 | RCT, Double-blind | Solriamfetol, Placebo |
| NCT03226522 Addressing Dementia Via Agitation-Centered Evaluation | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | P2P3 | Completed | 366 | RCT, Double-blind | AXS-05, Bupropion, Placebo |
| NCT04163185 Initiating Early Control of Migraine Pain and Associated Symptoms | Migraine | P3 | Completed | 302 | RCT, Double-blind | AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo |
| NCT05550207 Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) | Migraine | P3 | Completed | 100 | Open-label | AXS-07 (meloxicam-rizatriptan) |
| NCT06736509 An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | P3 | Terminated | 139 | Open-label | AXS-05 (dextromethorphan-bupropion) |
| NCT02746068 A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions | Osteoarthritis, Knee | P3 | Unknown | 346 | RCT, Double-blind | AXS-02, Placebo |
| NCT05059223 A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy | Narcolepsy, Cataplexy | P3 | Completed | 90 | RCT, Double-blind | AXS-12 (reboxetine), Placebo |
| NCT06878976 Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder | Binge-Eating Disorder | P3 | By Invite | 300 | Open-label | Solriamfetol 75mg, 150 mg, or 300 mg |
| NCT04039022 Open-Label Safety Study of AXS-05 in Subjects With Depression | Major Depressive Disorder, Treatment Resistant Depression | P3 | Completed | 876 | Open-label | AXS-05 (dextromethorphan and bupropion) oral tablets |
| NCT04797715 Assessing Clinical Outcomes in Alzheimer's Disease Agitation | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | P3 | Completed | 178 | RCT, Double-blind | AXS-05, Placebo |
| NCT04068051 Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) | Migraine | P3 | Completed | 706 | Open-label | AXS-07 |
| NCT02741791 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder | Treatment Resistant Major Depressive Disorder | P3 | Completed | 312 | RCT, Double-blind | AXS-05, Bupropion |
| NCT07637162 Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | Fibromyalgia | P3 | By Invite | 300 | Open-label | AXS-14 (esreboxetine) |
| NCT04019704 A Trial of AXS-05 in Patients With Major Depressive Disorder | Depression, Major Depressive Disorder | P3 | Completed | 327 | RCT, Double-blind | AXS-05, Placebo |
| NCT06360419 Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol | Major Depressive Disorder | P3 | Completed | 346 | RCT, Double-blind | Solriamfetol 300 mg, Placebo |
| NCT02504008 CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 | Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy | P3 | Unknown | 190 | RCT, Double-blind | AXS-02 (oral zoledronate), Placebo |
| NCT05113745 A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) | Narcolepsy, Cataplexy | P3 | Completed | 68 | RCT, Double-blind | AXS-12 (reboxetine), Placebo |
| NCT04947553 A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | P3 | Completed | 456 | RCT, Double-blind | AXS-05 (dextromethorphan-bupropion), Placebo |
| NCT05557409 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | P3 | Completed | 408 | RCT, Double-blind | AXS-05, Placebo |
| NCT05972044 A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) | ADHD | P3 | Completed | 516 | RCT, Double-blind | Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo |
| NCT03896009 Maximizing Outcomes in Treating Acute Migraine | Migraine | P3 | Completed | 1,594 | RCT, Double-blind | AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo |
| NCT04608396 Mechanistic Evaluation of Response in TRD (MERIT) | Treatment Resistant Depression, Major Depressive Disorder | P2 | Completed | 44 | RCT, Double-blind | AXS-05, Placebo |
| NCT04971291 An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients | Major Depressive Disorder, Treatment Resistant Depression | P2 | Unknown | 312 | RCT, Double-blind | AXS-05, Bupropion SR |
| NCT03595579 Assessing Symptomatic Clinical Episodes in Depression | Major Depressive Disorder | P2 | Completed | 97 | RCT, Double-blind | AXS-05, Bupropion |
| NCT04634669 Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) | Treatment Resistant Depression, Major Depressive Disorder | P2 | Terminated | 181 | Open-label | AXS-05 (dextromethorphan-bupropion) |
| NCT03471767 AXS-05 Phase II Trial on Smoking Behavior | Smoking Cessation, Smoking, Cigarette | P2 | Completed | 58 | RCT, Double-blind | AXS-05, Bupropion SR |
| NCT03881852 Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) | Narcolepsy, Cataplexy Narcolepsy | P2 | Completed | 21 | RCT, Double-blind | AXS-12 (Reboxetine), Placebo |
| NCT05008341 Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration | Narcolepsy, Obstructive Sleep Apnea | P1 | Completed | 6 | Open-label | Solriamfetol 150 mg Oral Tablet |